News | Magnetic Resonance Imaging (MRI) | October 17, 2023

Halo tapped to support Bayer’s phase III clinical development program, QUANTI  

Halo tapped to support Bayer’s phase III clinical development program, QUANTI

Getty Images


October 17, 2023 — Halo Precision Diagnostics, a leader in early disease detection using precision diagnostics, today announced a collaboration with Bayer, a global leader in radiology, to join QUANTI, Bayer’s Phase III clinical development program for gadoquatrane

Bayer initiated the QUANTI studies to evaluate the safety and efficacy of gadoquatrane, an investigational gadolinium-based contrast agent, in MRI. Contrast-enhanced MRI plays a key role in the healthcare continuum, providing a radiation-free imaging method to obtain detailed images of the body. 

HALO’s Indian Wells, California Innovation Center is one of Bayer’s first QUANTI partner sites globally and recently became the first to include a pediatric participant into the gadoquatranedevelopment program. 

“Our partnership with Bayer is the latest example of Halo leading the way when it comes to advancements supporting early disease detection,” said Bernadette Greenwood, chief research officer, Halo. “We are grateful to Bayer for its partnership and the opportunity to potentially impact the diagnostic pathway for patients.” 

The QUANTI clinical development program consists of three clinical trials: 

  • QUANTI CNS evaluates the efficacy and safety of gadoquatrane in adults with known or highly suspected pathologies of the central nervous system undergoing a contrast-enhanced MRI.  
  • QUANTI OBR investigates the safety and efficacy of gadoquatrane in contrast-enhanced MRI of all other body regions, such as head and neck, thorax, abdomen, pelvis, and extremities.  
  • QUANTI PEDS assesses the pharmacokinetics and safety of gadoquatrane in children aged 0-18 years undergoing contrast-enhanced MRI.  

Across the three studies, the QUANTI clinical development program expects to enroll 800 patients across 17 countries.  

“We perpetually aim to develop health care innovations that support patients and doctors managing health conditions,” said Marta Santiuste, R&D Clinical Development Head, Radiology at Bayer. “We’re very encouraged by the progress of our QUANTI development program and value Halo’s continued partnership and contributions.” 

Halo, through a growing network of owned and partner clinics and the company’s proprietary precision diagnostics platform, integrates advanced imaging with molecular diagnostics to deliver comprehensive clinical insights for early disease detection and treatment. The company has clinically validated care pathways for prostate cancer, breast cancer, and cardiovascular disease, as well as plans for neurodegenerative and other life-threatening diseases. 

For more information: www.halodx.com 

Bayer initiates Phase III Studies with Investigational Contrast Agent Gadoquatrane 

At RSNA, Bayer to Showcase Product Offerings and Announces Broadened AI Offering in Radiology 


Related Content

News | Radiology Business

December 4, 2023 — Ajay Gupta, MD, MS, has been named chair of the Department of Radiology at Columbia University ...

Time December 04, 2023
arrow
News | RSNA

December 1, 2023 — Royal Philips, a global leader in health technology, put patients and healthcare providers center ...

Time December 01, 2023
arrow
News | RSNA

December 1, 2023 —Nuance Communications, Inc., a Microsoft Company, during the 2023 Radiological Society of North ...

Time December 01, 2023
arrow
News | RSNA

December 1, 2023 — In today's healthcare environment, the industry faces various pressing challenges. The magnetic ...

Time December 01, 2023
arrow
News | Radiology Imaging

November 30, 2023 — Through its leading imaging solutions and commitment to innovation, GE HealthCare remains at the ...

Time November 30, 2023
arrow
News | Pediatric Imaging

November 30, 2023 — Youth baseball players are prone to elbow pain and injuries, including repetitive overuse changes ...

Time November 30, 2023
arrow
News | Artificial Intelligence

November 29, 2023 — The Radiological Society of North America (RSNA) has announced the results of the “RSNA Abdominal ...

Time November 29, 2023
arrow
News | Artificial Intelligence

November 29, 2023 —Flywheel, a leading medical imaging artificial intelligence (AI) development platform, today ...

Time November 29, 2023
arrow
News | Contrast Media

November 29, 2023 — Bayer continues to advance its comprehensive Radiology portfolio with progress in the development ...

Time November 29, 2023
arrow
News | RSNA

November 28, 2023 — Curtis P. Langlotz, MD, PhD, has taken the helm as 2023-2024 president of the Radiological Society ...

Time November 29, 2023
arrow
Subscribe Now